Published in Oncol Rep on September 19, 2014
Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46
Classification of papillomaviruses. Virology (2004) 14.16
Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008) 11.50
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer (2003) 8.01
Insulin-like growth factors and neoplasia. Nat Rev Cancer (2004) 6.29
Papillomaviruses in the causation of human cancers - a brief historical account. Virology (2009) 5.46
Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst (2000) 5.32
The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev (2006) 4.93
The insulin-like growth factor system and cancer. Cancer Lett (2003) 4.91
Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell (2004) 4.38
The age of cancer. Nature (2000) 4.32
Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med (2011) 3.84
Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) (2006) 3.74
The papillomavirus life cycle. J Clin Virol (2005) 3.41
Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A (1993) 2.58
The biology and life-cycle of human papillomaviruses. Vaccine (2012) 2.53
The human papillomavirus E7 oncoprotein. Virology (2008) 2.32
Minireview: IGF, Insulin, and Cancer. Endocrinology (2011) 2.16
Human papillomavirus vaccine introduction--the first five years. Vaccine (2012) 2.12
Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene (2003) 2.00
Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res (2008) 1.83
Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol (2004) 1.81
siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene (2003) 1.78
Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol (2004) 1.66
The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes (2009) 1.63
New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer (2002) 1.60
Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol (2011) 1.52
Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol (2008) 1.52
Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A (2005) 1.50
The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol (2005) 1.48
RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol (2003) 1.47
MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery (2013) 1.43
The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res (2007) 1.39
Lentiviral vectors: regulated gene expression. Mol Ther (2000) 1.39
Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther (2003) 1.38
The ABCs of IGF-I isoforms: impact on muscle hypertrophy and implications for repair. Appl Physiol Nutr Metab (2006) 1.38
Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab (2004) 1.37
Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res (2010) 1.36
Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol Metab (2010) 1.33
Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J Cell Sci (2003) 1.31
Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol (2010) 1.31
Papillomavirus E1 proteins: form, function, and features. Virus Genes (2002) 1.29
Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res (2005) 1.27
Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol (2009) 1.27
Cancer associated human papillomaviruses. Curr Opin Virol (2012) 1.25
Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer (2002) 1.24
The role of TP53 in Cervical carcinogenesis. Hum Mutat (2003) 1.23
The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res (2012) 1.21
The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer (2007) 1.20
A mitogenic peptide amide encoded within the E peptide domain of the insulin-like growth factor IB prohormone. Proc Natl Acad Sci U S A (1992) 1.19
Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid. Carcinogenesis (2004) 1.19
Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther (2006) 1.19
Folate is associated with the natural history of high-risk human papillomaviruses. Cancer Res (2004) 1.18
Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling. Carcinogenesis (2006) 1.16
Human papillomavirus and molecular considerations for cancer risk. Cancer (2008) 1.12
Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res (2007) 1.11
Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res (2012) 1.11
Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem (2002) 1.11
T-antigen of the human polyomavirus JC attenuates faithful DNA repair by forcing nuclear interaction between IRS-1 and Rad51. J Cell Physiol (2006) 1.08
The GH-IGF1 axis and longevity. The paradigm of IGF1 deficiency. Hormones (Athens) (2008) 1.07
Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci (2009) 1.06
Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle (2012) 1.06
Large-scale pooled next-generation sequencing of 1077 genes to identify genetic causes of short stature. J Clin Endocrinol Metab (2013) 1.01
Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res (1996) 1.01
IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1-induced mitogenesis. J Virol (2004) 1.00
Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol (2013) 1.00
Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3. Mol Cell Biol (2000) 1.00
Nucleolar localization of an isoform of the IGF-I precursor. BMC Cell Biol (2002) 1.00
Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res (2000) 0.99
The insulin receptor substrate-1: a biomarker for cancer? Exp Cell Res (2008) 0.99
Customizing the targeting of IGF-1 receptor. Future Oncol (2009) 0.98
JC virus large T-antigen and IGF-I signaling system merge to affect DNA repair and genomic integrity. J Cell Physiol (2006) 0.96
Gene expression profiles in cells transformed by overexpression of the IGF-I receptor. Oncogene (2005) 0.95
The decline and fall of the IGF-I receptor. J Cell Physiol (2013) 0.95
Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res (2003) 0.94
The pro-forms of insulin-like growth factor I (IGF-I) are predominant in skeletal muscle and alter IGF-I receptor activation. Endocrinology (2013) 0.91
Progesterone signaling inhibits cervical carcinogenesis in mice. Am J Pathol (2013) 0.90
Mutations in the D-loop region and increased copy number of mitochondrial DNA in human laryngeal squamous cell carcinoma. Mol Biol Rep (2012) 0.90
Do human papillomaviruses target epidermal stem cells? Dermatology (2003) 0.89
Insulin-like growth factor axis and oncogenic human papillomavirus natural history. Cancer Epidemiol Biomarkers Prev (2008) 0.88
Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat (2004) 0.87
Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. Br J Cancer (2008) 0.87
Differential expression of IGF-I and insulin receptor isoforms in HPV positive and negative human cervical cancer cell lines. Horm Metab Res (2008) 0.87
Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther (2009) 0.86
Indian women with higher serum concentrations of folate and vitamin B12 are significantly less likely to be infected with carcinogenic or high-risk (HR) types of human papillomaviruses (HPVs). Int J Womens Health (2010) 0.86
Alterations in mtDNA: a qualitative and quantitative study associated with cervical cancer development. Gynecol Oncol (2013) 0.86
Association between components of the insulin-like growth factor system and epithelial ovarian cancer risk. Oncology (2004) 0.85
Virological characteristics of cervical cancers carrying pure episomal form of HPV16 genome. Gynecol Oncol (2013) 0.85
Genetics of isolated growth hormone deficiency. J Clin Res Pediatr Endocrinol (2010) 0.85
Lentivirus-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of cystic fibrosis. Gene Ther (2004) 0.85
Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Gynecol Oncol (2005) 0.84
Differential expression of IGF-1 mRNA isoforms in colorectal carcinoma and normal colon tissue. Int J Oncol (2012) 0.84
Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins. Am J Pathol (2002) 0.83
John Cunningham virus T-antigen expression in anal carcinoma. Cancer (2010) 0.83
IGF1 mRNA isoform expression in the cervix of HPV-positive women with pre-cancerous and cancer lesions. Exp Ther Med (2010) 0.83
Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Biomedica (2006) 0.82
Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy. Anticancer Res (2010) 0.82
Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine (2003) 0.82
Regulation of nuclear receptor activities by two human papillomavirus type 18 oncoproteins, E6 and E7. Biochem Biophys Res Commun (2003) 0.82